Non-invasive prenatal testing is a procedure to determine the genetic abnormalities of the fetus. The procedure is used to screen fetus for genetic disorders such as, Down syndrome, Edwards syndrome and Patausyndrome. The test is basically recommended to elder women at high risk for carrying baby with genetic abnormalities.
Increasing age maternal age around the world and rising number of working women in developing regions are contributing significantly to the market growth. Advancing maternal age increases number of the risk of genetic disorders in babies resulting in abnormalities such as microcephaly, short neck, upward slanted eyes, poor muscle tone, heart, intestine, and breathing problems. In addition, high demand for non-invasive techniques and technological advancements by manufacturers to offer better solutions are expected to continue rising in the coming years. For instance, In November 2016, GE Healthcare launchedLOGIQ E9 XDclear 2.0 ultrasound system and showcased 25 new products at the Radiological Society of North America (RSNA). These products provide improved performance and better clinical results for clinicians and hospitals globally.
Global non-invasive prenatal testing market accounted for over USD 1.75 billion in 2017 and is expected to grow at a CAGR of 18.37% during the forecast period, 2019–2026.
To learn more about key trends >> Download Sample Report
Global non-invasive prenatal testing market is segmented by product, method, application and end user.
By Product, the market is segmented into consumables and instruments. Consumables are expected to grow at the fastest CAGR as these are more preferred over instruments and always in high demand. It is further segmented into assay kits & reagents and disposables.
By Method, the non-invasive prenatal testing market is segmented into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma test and fetal cells in maternal blood tests. The ultrasound detection is expected to hold the largest market share as it is cost effective and widely available in developing regions.
Based on application,non-invasive prenatal testing market is segmented into trisomy, microdeletion syndrome and other application. Trisomy segment can grow at the highest CAGR during the forecast period on account of increasing incidences of chromosomal abnormalities with increasing maternal gap.
Based on end user, non-invasive prenatal testing market is segmented into diagnostic laboratories and hospitals. The diagnostic laboratories expected to hold the largest market share. Efforts by companies to provide advanced products to diagnostic laboratories is contributing to the growth of the segment.
Geographically, the global non-invasive prenatal testing market is segmented into four regions: North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa (LAMEA).
To understand geography trends >> Download Sample Report
North America is likely to lead the non-invasive prenatal testing market due to increase in number of maternal age. For instance, according to CDC, in 2016, around 10% of babies were born to first-time mothers at the age of 35 years or older. In addition, the average age of first-time mothers rose from 24.9 years in 2000 to 26.3 years in 2014 in the U.S.
Asia Pacific non-invasive prenatal testing market is expected to witness significant growth on account of increasing cases of miscarriages due to insufficient nutritional intake during pregnancy, decreased fertility and increasing maternal age due to rise in number of working women in the region especially in India and China. According to Australian Bureau of Statistics, 2015, the average age of first-time mothers increased from 27.8 years in 2003 to 28.6 years in 2013.
Europe is likely to emerge as the third largest non-invasive prenatal testing market globally. This can be attributed to the rising number to the maternal age in the region. For instance, Eurostat reported in 2013, around 40.6% first time mothers belonged to the age group of 30 years and above. Additionally, around 65,500 births of first children were reported in women aged more than 40 years in the same year.
LAMEAis expected to witness steady growth in the forecast period. Lack of awareness about these technologies and poor economic condition of African countries are the factors for steady growth of the market.
Some of the key players in the global non-invasive prenatal testing market are Thermo Fisher Scientific, Illumina, Inc, F. Hoffmann-La Roche Ltd, Pacific Biosciences of California, QIAGEN N.V., PerkinElmer, Inc, Agilent Technologies, Inc., Beijing Genomics Institute, Koninklijke Philips N.V., and GE Healthcare.
|Market Size||USD in Billion By 2030|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
|Segments Covered||by Product (Consumables, Instruments), Method, Application, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, LAME and Rest of the World|
|Key Companies Profiled/Vendors||Thermo Fisher Scientific, Illumina, Inc, F. Hoffmann-La Roche Ltd, Pacific Biosciences of California, QIAGEN N.V., PerkinElmer, Inc, Agilent Technologies, Inc., Beijing Genomics Institute, Koninklijke Philips N.V., and GE Healthcare.,|
|Key Market Opportunities||High Demand For Non-Invasive Techniques And Technological Advancements By Manufacturers|